Kaitai Capital

Sheng Sheng Biology is a biotechnology company that provides medical research and experimental development services.

Xinyue Ltd. is an online audio and video production platform based in Shanghai, China, founded in 2017. The company provides a suite of tools that facilitate the review, automatic sorting, collaboration, and sharing of video content. Its platform enables users to conduct video comparisons and manage comments efficiently, streamlining the production process. Additionally, Xinyue offers a mobile application that enhances accessibility, allowing users to manage video content on the go. The platform integrates digital cloud technology, enabling real-time synchronization of video data captured from cameras to a cloud server, which supports convenient storage, sharing, and further production efforts.

TechnoDerma Medicines is a private clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for various skin diseases. The company focuses on creating small molecular drugs aimed at treating conditions such as androgenetic alopecia, atopic dermatitis, psoriasis, lupus erythematosus, and scars. By prioritizing research and development, TechnoDerma Medicines seeks to provide patients with safe and effective treatment options to improve their quality of life and address unmet medical needs in dermatological care.

Minova Pharma develops novel pharmaceutical formulations and small molecule therapies to treat disfiguring diseases and mental health conditions. The company focuses on research and development of innovative drugs and complex formulations, with products in clinical and preclinical stages. Its work targets hair loss, acne, depression, and photoaging, aiming to provide new therapeutic options for cosmetic and psychological needs.

Phanes Therapeutics is a biotechnology company specializing in drug discovery for immuno-oncology and eye diseases. Established in 2016, the company focuses on developing monoclonal antibodies for solid tumors and conditions like age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, they work on bispecific antibodies targeting small cell lung cancer.

Avirmax specializes in the research, development, and manufacturing of adeno-associated virus vectors for gene therapies targeting chronic eye diseases. Located in Hayward, California, the company focuses on innovative technologies to enhance viral vector production.

Genemagic Biosciences is a biotechnology company specializing in the development of regenerative medicines and therapies for neurological and ocular diseases. The company's core technologies include in vivo cell reprogramming, anti-cell death strategies, and adeno-associated virus (AAV) capsid discovery. These innovations aim to reconstruct lost neurons in the central nervous system and retina, and protect disease-related neurons, offering potential cures for patients with these conditions.

Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

Atom Bioscience is a clinical-stage biotechnology company dedicated to developing innovative therapies for inflammatory and metabolic diseases. The company focuses on conditions such as chronic gout and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and certain cancers. By concentrating on the intersections of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these challenging health issues.

Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.

Huaboron Neutron is a biotechnology company that develops boron drugs and boron neutron capture therapy devices for the diagnosis of malignant cancers.

Levinthal is a company specializing in AI-driven protein design, focusing on enhancing industrial production of biological molecules and microbes. Their platform offers services that leverage artificial intelligence for applications in food safety, medical care, synthetic biology, feed, cosmetics, and environmental protection. The company develops advanced algorithms and experimental technologies to enable enterprises to design more stable and efficient enzymes, thereby improving various industrial processes.

Chiplego focuses on embedded high-performance computing systems that assist in the creation of a mobile digital world and a better travel and life experience for everyone.

Xihu Xinchen is a technology company focusing on the research and development of artificial intelligence services.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Yuanqi Pharmaceutical is a biotechnology company that offers custom synthesis services for compounds, molecules, and raw materials.

Beijing ICAN Technology Co. Ltd., established in 2016, specializes in precision agriculture and weather station operations. The company develops a comprehensive big data platform that integrates weather, soil, crop management, and pest data. ICAN also offers seed production and breeding services, utilizing a system that includes a database, statistical software, and IoT systems for real-time data collection. With over 100 private weather stations across China, ICAN serves leading seed companies and aims to profitably drive precision agriculture practices.

Compass Biotechnology (Xinjiang) is a biotechnology developer focused on genomics applications of industry side.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Primelink Bio is a biotechnology firm focused on developing advanced drug delivery systems, particularly through antibody-drug conjugate (ADC) technology. The company employs a flexible and modular platform to synthesize a diverse library of ADC drug candidates. By utilizing bioconjugation technology, Primelink Bio aims to identify optimal drug compositions tailored for specific targets, thereby enhancing treatment effectiveness for cancer patients. Through its innovative approach, the firm seeks to improve therapeutic outcomes and contribute significantly to the field of cancer treatment.

Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.

Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

Realibox is a technology company that specializes in providing advanced online platforms for collaborative 3D digital design and cloud-based solutions. They primarily serve global consumer manufacturing companies, helping them accelerate product innovation and drive digital transformation. For industrial product designers, Realibox offers an all-in-one platform for online collaboration, management, and empowerment of production and marketing processes. By integrating 3D design data, the platform enhances teamwork, reduces product launch cycles, and facilitates business upgrades while fostering creativity.

Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for allergies and autoimmune diseases. The company aims to address high unmet medical needs through a robust pipeline that utilizes two core technology platforms, PCFiT and Apitope, alongside collaborations with external partners. Worg also works on a platform for molecular allergy diagnosis, further enhancing its capabilities in the allergy treatment domain. By leveraging both internal development and flexible partner models, Worg Pharmaceuticals seeks to expedite the advancement of effective therapies and improve patient outcomes in the field of immunotherapy.

Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.

Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.

Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Wangfanxin is an enterprise digital transformation solution provider. Based on the application of process mining, it mainly provides services such as process visualization, process variation, and analysis of process data.

Apache DolphinScheduler is a distributed and extensible workflow scheduler platform with powerful DAG visual interfaces.

Yiwise is an artificial intelligence company focused on research and development, particularly in the areas of natural language processing and human-computer interaction. The company specializes in dialogue interaction technology that enhances the ability of enterprises to engage with a large customer base effectively. By leveraging advanced voice intelligence technology, Yiwise improves efficiency in sectors such as telemarketing and customer service. Their solutions incorporate autonomous speech configuration and multi-party real-time communication driven by deep learning algorithms, allowing for optimized interactions between humans and machines. Yiwise aims to deliver refined and intelligent operational capabilities that support enterprises in achieving better customer engagement and satisfaction.

Worktile Technology, established in 2013, is a Chinese software company headquartered in Beijing, with offices in Shanghai, Shenzhen, and Xi'an. It specializes in a web and mobile-based project management tool, designed to enhance team collaboration and productivity among developers and professionals. The platform facilitates task management, communication, and document sharing, aiming to streamline work processes and improve overall enterprise efficiency.

Pleryon Therapeutics is a drug delivery platform company focusing on polymer-based biopharmaceutical technologies. Its platform enables precise control of drug release and improved efficacy across diverse molecules and indications. By addressing unmet clinical needs, Pleryon aims to deliver targeted, sustained therapies that enhance treatment performance and broaden therapeutic possibilities. It collaborates with pharmaceutical partners and healthcare providers to translate its technologies into practical therapies, contributing to improved patient outcomes and quality of life.

Ke Ning Bio is an ophthalmic pharmaceutical manufacturer dedicated to developing ophthalmic drugs.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

TaoCloud specializes in intelligent software-defined storage solutions tailored for enterprise-level customers. The company focuses on developing distributed data storage and management software that enhances the efficiency and ease of use for its clients. Through significant long-term investments in research and development, TaoCloud has advanced its product offerings from the first-generation capacity software-defined storage to the second-generation performance-extreme all-flash solutions. This evolution positions the company as a leader in the next generation of all-flash software-defined storage, establishing strong technological barriers and competitiveness in the market.

Juncell Therapeutics is a biopharmaceutical company focused on developing innovative therapies for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are then cultivated outside the human body before being reintroduced to patients, aiming to enhance the body's ability to combat tumors while minimizing side effects. Through its research and development efforts, Juncell Therapeutics seeks to advance treatment options in the medical industry, ultimately improving patient outcomes in cancer therapy.

Junsai Shengwu developes therapies for new solid tumor cell.

Atom Bioscience is a clinical-stage biotechnology company dedicated to developing innovative therapies for inflammatory and metabolic diseases. The company focuses on conditions such as chronic gout and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and certain cancers. By concentrating on the intersections of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these challenging health issues.

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Ceram Pharmaceuticals is a biotech firm that uses epigenetics to carry out R&D of drugs and diagnostic treatments for cancer and diseases.

Juwei Yuanchuang is a biotechnology company that produces fermentation raw materials out of agricultural and animal husbandry wastes.

Dashi Pharmaceuticals is a pharmaceutical company that provides anti-body drug research and development and molecular engineering solutions.

LifeFoundry, Inc., established in 2016, is a biotechnology research company headquartered in Pleasanton, California, with additional offices in Champaign, Illinois, and China. The company specializes in providing research and development services to biotech firms, utilizing synthetic biology and robotics. LifeFoundry assists fermentation companies in creating large, customized bacterial collections with specific mutations, enabling industrialized, high-throughput, and flexible engineering of biological systems for practical applications.

DigiCodon is an IT company that offers hardware and software integration, hierarchical storage architecture, and data integration solutions.

West Lake Xinchen is an AI psychological service technology company, committed to creating an inclusive, scientific, intelligent and professional AI psychological service platform, and insisting on providing customers with scientific and rigorous psychological services.

Xihu Xinchen is a technology company focusing on the research and development of artificial intelligence services.

TianTi Biotherapeutics is a biotechnology company focused on the research and development of antibody drugs. It has developed the Ablink platform, which enhances drug discovery by screening and constructing libraries of up to tens of millions of single B cells. This technology significantly improves the efficiency of antibody development, allowing drug companies to produce higher quality antibodies for therapeutic use. Through its innovative approach, TianTi Biotherapeutics aims to advance the field of biopharmaceuticals and contribute to the development of effective medical treatments.

Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform.

CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Rongzhi Information is a robotic process automation software developer focusing on the application of AI technology in the enterprise.

Zhinian Technology is a big data solution provider that develops a system with a memory-based distributed database & computing framework. The system also provides a complete set of big data process services including vector-based programming language, data query, cleaning, analysis, modeling, and visualization.

Redesign Science, established in 2017 and based in New York, is a biotechnology company specializing in small molecule drug discovery. It employs a computational chemistry platform to accelerate drug development by simulating protein targets at the atomic level, revealing subtle drug opportunities that traditional methods may miss. The company aims to set a new standard in early-stage drug discovery, leveraging first-principles physics and artificial intelligence to create generative AI for drug discovery, with a focus on high unmet medical needs.

BioBin Data Science is an innovative agricultural high-tech enterprise focused on research and development in bioinformatics and plant breeding. The company specializes in creating advanced tools for plant breeding, including software and hardware solutions for data analysis, custom development, and strategic design. Its primary offering is a platform that analyzes test data and comparisons of various crop varieties, assisting breeders in evaluating characteristics such as stability and regional adaptability. This platform simplifies the reporting process, enabling users to generate comprehensive reports with a single click, thereby enhancing the efficiency and effectiveness of the breeding process.

MingSight Pharmaceuticals is focused on developing innovative ophthalmic drugs, particularly targeting diabetic retinopathy and related conditions. The company is conducting a clinical trial for its novel drug, MS-553, which represents the first clinical evaluation of this treatment for diabetic retinopathy. MS-553 is a highly selective protein kinase C (PKC) inhibitor that can be administered orally, offering a less invasive alternative to traditional intraocular injections, which can pose safety risks. In addition to its applications in diabetic retinopathy, MS-553 has shown promise in treating chronic lymphocytic leukemia (CLL) and diabetic macular edema (DME), demonstrating significant efficacy and market potential. The drug can be used alone or in combination with existing therapies, addressing specific mutations in patients and improving treatment outcomes.

Axbio is a Shenzhen-based company developing and manufacturing advanced gene sequencing and diagnostic technology. It offers sequencing and diagnostic systems, disposable biochips, reagents, and genome extraction kits for stool, blood, and saliva, as well as bacterial DNA extraction kits. It also develops semiconductor-based Bio-CMOS chips and microfluidic platforms designed for high-throughput sequencing and molecular diagnostics. Its platform supports a spectrum of applications from handheld bedside devices to fully automated instruments for laboratories and hospitals, enabling services such as early cancer screening, rapid pathogen detection, and drug development.

Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.

Ai Industry provides cosmetic product development and supply chain management services. They ensure the environmental sustainability of the overall solution and provide customers with real-time data on the end-to-end life cycle of the product.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

HighlightLL Pharma is a pharmaceutical company focused on developing drugs for immune diseases and tumors. The company is dedicated to creating innovative product lines that possess global competitive advantages. By leveraging its unique pharmacological, biological, and clinical capabilities, HighlightLL Pharma aims to provide patients with safe and affordable treatment options.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

BridGene Biosciences is a biotechnology company focused on discovering and developing innovative small molecules aimed at traditionally untreatable targets. By utilizing advanced chemoproteomic technology, the company facilitates proteome-wide screening in live cells, which allows for the identification of highly selective small molecules. BridGene employs a combination of covalent chemistry, chemical proteomics, and quantitative mass spectrometry to create therapeutics and covalent small-molecule inhibitors. This approach positions BridGene to enable the healthcare industry to uncover new drug targets and develop effective treatments for challenging conditions.

Elevoc is an AI-powered audio solution provider focused on enhancing voice clarity and intelligibility in various applications. The company has developed a pioneering deep learning-based voice enhancement solution, which is recognized as the world's first real-time technology of its kind for smart devices and communication platforms. Elevoc's innovative approach allows for the extraction of speech from background noise, significantly improving user experience across millions of devices globally. The company's expertise encompasses advanced algorithms and hardware tailored for intelligent noise reduction, echo cancellation, reverberation suppression, sound source localization, and beamforming. Elevoc's solutions cater to diverse sectors, including education, automotive, and security, facilitating enhanced voice signal processing and intelligent voice interaction.

PackGene Biotech is a United States-based contract research organization and contract development and manufacturing organization that specializes in viral vectors for gene therapies. The company focuses on adeno-associated virus (AAV) vector design, cloning and packaging, as well as production of AAV, lentiviral vectors, mRNA, and plasmid DNA. It serves early-stage drug discovery, preclinical development, and cell and gene therapy trials, delivering scalable, cost-effective production with emphasis on purity, titer and infectivity. PackGene offers customized vector design, construction, and packaging services to support researchers in accelerating gene therapy programs.

Juncell Therapeutics is a biopharmaceutical company focused on developing innovative therapies for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are then cultivated outside the human body before being reintroduced to patients, aiming to enhance the body's ability to combat tumors while minimizing side effects. Through its research and development efforts, Juncell Therapeutics seeks to advance treatment options in the medical industry, ultimately improving patient outcomes in cancer therapy.

Teon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood, California, focused on advancing cancer immunotherapy. Founded in 2018, the company specializes in the discovery and development of small molecule drugs aimed at inhibiting immunosuppressive and cancer-promoting signaling pathways within the tumor microenvironment. Teon Therapeutics is dedicated to improving the lives of cancer patients by developing a targeted portfolio of molecules that not only restore antitumor immunity but also suppress cancer cell proliferation. Their lead program involves an A2BR-specific antagonist that is set to enter Phase 1b clinical trials. By integrating metabolic checkpoint inhibitors and GPCR immune checkpoint inhibitors, Teon aims to enhance the efficacy of existing immunotherapies and improve long-term outcomes for cancer patients.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for allergies and autoimmune diseases. The company aims to address high unmet medical needs through a robust pipeline that utilizes two core technology platforms, PCFiT and Apitope, alongside collaborations with external partners. Worg also works on a platform for molecular allergy diagnosis, further enhancing its capabilities in the allergy treatment domain. By leveraging both internal development and flexible partner models, Worg Pharmaceuticals seeks to expedite the advancement of effective therapies and improve patient outcomes in the field of immunotherapy.

Quadriga BioSciences, Inc. is a pharmaceutical company based in Los Altos, California, that focuses on developing proprietary targeted therapies for cancer treatment. Founded in 2011, the company leverages the discovery that aggressive cancer cells often over-express specific amino acid transporters on their surfaces, which facilitate nutrient intake essential for tumor growth. By exploiting this biological characteristic, Quadriga is creating innovative targeted molecules aimed at selectively attacking cancer cells that exhibit these transporters. This approach aims to provide personalized medicine and enable healthcare professionals to offer safer and more effective treatment options for cancer patients.

Youxin Cloud is a cloud service company specializing in Platform-as-a-Service (PaaS). It offers digital transformation solutions, focusing on cloud computing and big data services for enterprise clients.

AcroImmune is a biotechnology company focused on the development of immunotherapy drugs aimed at treating malignant tumors and inflammatory diseases. The company specializes in creating both first-in-class and best-in-class therapies, providing innovative treatment options for patients suffering from various forms of cancer and related conditions. By leveraging advanced biotechnological approaches, AcroImmune seeks to enhance the effectiveness of cancer treatments and improve patient outcomes in the field of immunotherapy.

Oxford Biotherapeutics Ltd is a biotechnology company focused on developing innovative antibody therapies for cancer treatment. The company specializes in antibody-drug conjugates, aiming to create targeted therapies that improve treatment outcomes for patients. Its proprietary OGAP (Oxford Genome Anatomy Project) platform, one of the largest human protein databases globally, facilitates the identification of validated and novel antigen targets across various cancer types. Key products include OBT076, an antibody-drug conjugate aimed at treating high-risk HER2 negative breast cancer and other solid tumors. Additionally, Oxford Biotherapeutics is developing antibody-based treatments for conditions such as acute myeloid leukemia and plans to integrate companion diagnostics into its programs to enhance disease management. Established in 2003, the company is based in Oxon, United Kingdom, with an operational site in San Jose, California, and maintains strategic collaborations with leading antibody-focused firms to broaden its therapeutic pipeline.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Totient Inc. is an AI-driven biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in using advanced machine learning and immunoinformatics to analyze complex datasets in the field of drug discovery and development. It focuses on identifying novel tissue-specific antigens and reconstructing high-affinity antibody therapeutics from tissues impacted by cancer, autoimmune diseases, and infections. By leveraging its platform's unique capabilities, Totient aims to quickly and accurately identify potent antibody candidates suitable for a variety of therapeutic applications, including cell therapies and bispecific antibodies. This innovative approach positions the company to address significant medical challenges in multiple areas of healthcare.

OncoImmune is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for cancer and autoimmune diseases. Its pipeline includes CD24Fc, a fusion protein for preventing acute graft-versus-host disease, and ONC-392, a monoclonal antibody designed to reduce immune-related toxicities.

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Atom Bioscience is a clinical-stage biotechnology company dedicated to developing innovative therapies for inflammatory and metabolic diseases. The company focuses on conditions such as chronic gout and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and certain cancers. By concentrating on the intersections of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these challenging health issues.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Yunying Medical specializes in gene mutation, methylation detection, and recombination solutions for cancer diagnosis and treatment.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Asieris Pharmaceuticals Co. Ltd. is a biotechnology company based in Taizhou, China, founded in 2010. The company is dedicated to the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. By focusing on oncology and infectious diseases, Asieris Pharmaceuticals seeks to develop innovative therapies that meet the medical needs of patients both in China and globally.

F&S Pharmatech is a pharmaceutical technology company based in Nanjing, China, specializing in the development of differentiated generic drugs and pharmaceutical intermediates. The company is engaged in the research and development of advanced pharmaceutical chemicals, including notable products such as sacubitril and diphenyl piperidine methanol. F&S Pharmatech offers contract manufacturing organization (CMO) services, alongside providing intellectual property solutions and environmentally friendly chemical technologies. Its focus on delivering reliable products supports research and development centers and generic drug developers, aiming to shorten development cycles and reduce product costs within the healthcare industry.

Mockplus is a web-based collaborative design platform that facilitates interaction among designers, product managers, and developers to enhance the design process. The platform offers a suite of tools, including Mockplus Classic, Mockplus RP, and Mockplus Cloud, which support prototyping, design import from mainstream software, and project management. By enabling teams to collaborate effectively and streamline their workflows, Mockplus aims to make design faster and more efficient. The platform is specifically designed to improve teamwork in creating and managing design systems, ensuring a smoother handoff to developers for finalization.

Sansong Medical Group provides building construction, industry resource integration, and mergers and acquisitions of nephrology hospitals.

Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Amphivena Therapeutics, Inc. is a clinical-stage immuno-oncology company based in South San Francisco, California, dedicated to developing bifunctional antibody therapies for hematologic malignancies. Founded in 2012, the company focuses on eradicating blood cancers by leveraging the patient's immune system to target and destroy tumor cells and their precursors. Amphivena's proprietary ReSTORE platform creates dual-action biologics that not only relieve immune suppression but also activate T cell effector functions in cancer patients. This platform is designed with features such as avid binding, target selectivity, and enhanced safety, and can be further engineered to include solid tumor targeting capabilities. By offering differentiated cancer immunotherapies, Amphivena Therapeutics aims to provide new treatment options for patients who are underserved by existing immunotherapies.

iLabService is a company that specializes in laboratory monitoring, management, and automation services through the use of Internet of Things (IoT) and artificial intelligence (AI) technologies. Founded in 2016 and headquartered in Shanghai, China, with additional offices in Hangzhou, Silicon Valley, and New Jersey, iLabService designs and manufactures sensor-based devices known as INTELAB DAQ. These devices monitor lab equipment and provide alerts when issues arise. The company also offers a software application that transforms lab data into actionable insights through analytics, simplifying operations in biotechnology and pharmaceutical labs. By providing subscription monitoring services and integrating various laboratory operations onto a single platform, iLabService enhances efficiency and reduces costs for laboratory managers.

PackGene Biotech is a United States-based contract research organization and contract development and manufacturing organization that specializes in viral vectors for gene therapies. The company focuses on adeno-associated virus (AAV) vector design, cloning and packaging, as well as production of AAV, lentiviral vectors, mRNA, and plasmid DNA. It serves early-stage drug discovery, preclinical development, and cell and gene therapy trials, delivering scalable, cost-effective production with emphasis on purity, titer and infectivity. PackGene offers customized vector design, construction, and packaging services to support researchers in accelerating gene therapy programs.

Forkhead BioTherapeutics Inc. is a biopharmaceutical company focused on developing innovative oral therapies for insulin-dependent diabetes. Founded in 2017 and based in New York, the company is working on Foxin, an oral agent designed to target and delete the FOXO1 protein. This mechanism aims to restore normal insulin production and regulate glucose metabolism, potentially transforming the management of diabetes. Forkhead BioTherapeutics harnesses the natural processes of cell conversion and regeneration to create therapies that significantly enhance patients' lives.

Sorghum Pharmaceuticals develops small molecule targeted innovative drugs for the unmet medical needs of autoimmune diseases and tumors. In the direction of unmet medical needs in autoimmune diseases and tumors, Gaochun Pharmaceuticals is committed to creating innovative product lines with global competitive advantages by leveraging its distinctive pharmaceutical, biological and clinical capabilities.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Zhejiang Daoer Biotechnology Co., Ltd. is a biopharmaceutical company based in the Xiasha Economic Development Zone of Hangzhou, Zhejiang Province. The company specializes in the development and research of protein drugs aimed at treating metabolic diseases, ophthalmology, and cancer. Utilizing an innovative platform called xLONGylation, which involves recombinant PEG-like polypeptides, Daoer Biologics enhances drug targeting and safety. Their approach includes the use of activated antibodies for precision tumor therapy and multi-targeted biotherapeutics that facilitate the creation of effective treatments for various medical conditions. Through these advanced methodologies, Daoer Biologics aims to improve therapeutic outcomes in oncology, metabolic disorders, and eye-related diseases.

Wangbaoba is a oatmeal brand, and consumers can buy it through some shopping platforms

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.